8 volume of contrast as much as possible is recommended. Best way to prevent CIN is to identify patients at high risk and provide adequate volume administration. However, use of sodium bicarbonate or N-Acetylcysteine in its prevention remains inconclusive in light of available evidence. Although the role of various drugs in prevention remains controversial, nephrotoxic drugs should be avoided before and after the procedure. Also, there still is no conclusive evidence to recommend gadolinium as a better alternative to iodinated contrast media in order to prevent CIN. Conﬂict of Interests The authors declare that they have no conﬂict d interests. References [1] J. H. Ix, M. G. Shlipak, H. H. Liu, N. B. Schiller, and M. A. Whooley, “Association between renal insuﬃciency and inducible ischemia in patients with coronary artery disease: the heart and soul study,” Journal of the American Society of Nephrology, vol. 14, no. 12, pp. 3233–3238, 2003. [2] N. S. Anavekar, J. J. V. McMurray, E. J. Velazquez et al., “Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction,” New England Journal of Medicine, vol. 351, no. 13, pp. 1285–1295, 2004. [3] M. G. Shlipak, G. L. Smith, S. S. Rathore, B. M. Massie, and H. M. Krumholz, “Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2195–2203, 2004. [4] N. Dimkovic´, “Cardiovascular diseases in patients with chronic renal diseases,” Srpski Arhiv za Celokupno Lekarstvo, vol. 136, pp. 135–141, 2008. [5] T. Ohtake, S. Kobayashi, H. Moriya et al., “High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1141–1148, 2005. [6] A. Levin, “Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis,” Seminars in Dialysis, vol. 16, no. 2, pp. 101–105, 2003. [7] A. J. Collins, “Cardiovascular mortality in end-stage renal disease,” American Journal of the Medical Sciences, vol. 325, no. 4, pp. 163–167, 2003. [8] A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. [9] R. Mehran and E. Nikolsky, “Contrast-induced nephropathy: deﬁnition, epidemiology, and patients at risk,” Kidney Inter- national, no. 100, supplement, pp. S11–S15, 2006. [10] J. R. Brown, D. J. Malenka, J. T. DeVries et al., “Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry,” Catheterization and Cardio- vascular Interventions, vol. 72, no. 3, pp. 347–354, 2008. [11] H. M. Sadeghi, G. W. Stone, C. L. Grines et al., “Impact of renal insuﬃciency in patients undergoing primary angio- plasty for acute myocardial infarction,” Circulation, vol. 108, no. 22, pp. 2769–2775, 2003. Cardiology Research and Practice [12] H. S. Thomsen and S. K. Morcos, “Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines,” British Journal of Radiology, vol. 76, no. 908, pp. 513–518, 2003. [13] H. S. Thomsen and S. K. Morcos, “Contrast-medium- induced nephropathy: is there a new consensus? A review of published guidelines,” European Radiology, vol. 16, no. 8, pp. 1835–1840, 2006. [14] R. G. Brindis, S. Fitzgerald, H. V. Anderson, R. E. Shaw, W. S. Weintraub, and J. F. Williams, “The American College of Cardiology-National Cardiovascular Data RegistryTM (ACC- NCDRTM): building a national clinical data repository,” Journal of the American College of Cardiology, vol. 37, no. 8, pp. 2240–2244, 2001. [15] K. J. Harjai, A. Raizada, C. Shenoy et al., “A Comparison of contemporary deﬁnitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system,” American Journal of Cardiology, vol. 101, no. 6, pp. 812–819, 2008. [16] P. Parfrey, “The clinical epidemiology of contrast-induced nephropathy,” CardioVascular and Interventional Radiology, vol. 28, supplement 2, pp. S3–S11, 2005. [17] C. S. Rihal, S. C. Textor, D. E. Grill et al., “Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention,” Circulation, vol. 105, no. 19, pp. 2259–2264, 2002. [18] C. Haller and I. Hizoh, “The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro,” Investigative Radiology, vol. 39, no. 3, pp. 149–154, 2004. [19] P. A. McCullough, “Radiocontrast-induced acute kidney injury,” Nephron Physiology, vol. 109, no. 4, pp. p61–p72, 2008. [20] R. E. Katholi, W. T. Woods Jr., G. J. Taylor et al., “Oxygen free radicals and contrast nephropathy,” American Journal of Kidney Diseases, vol. 32, no. 1, pp. 64–71, 1998. [21] S. N. Heyman, J. Reichman, and M. Brezis, “Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia,” Investigative Radiology, vol. 34, no. 11, pp. 685–691, 1999. [22] M. Dickenmann, T. Oettl, and M. J. Mihatsch, “Osmotic nephrosis: acute kidney injury with accumulation of proxi- mal tubular lysosomes due to administration of exogenous solutes,” American Journal of Kidney Diseases, vol. 51, no. 3, pp. 491–503, 2008. [23] J. F. Moreau, D. Droz, and L. H. Noel, “Tubular nephrotoxi- city of water-soluble iodinated contrast media,” Investigative Radiology, vol. 15, no. 6, pp. S54–S60, 1980. [24] S. L. Chen, J. Zhang, F. Yei et al., “Clinical outcomes of contrast-induced nephropathy in patients undergoing per- cutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the eﬀect of hydration and acetylcysteine,” International Journal of Cardiology, vol. 126, no. 3, pp. 407–413, 2008. [25] M. J. Gussenhoven, J. Ravensbergen, J. H. van Bockel et al., “Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease,” Journal of Cardiovascular Surgery, vol. 32, p. 81, 1991. [26] G. Dangas, I. Iakovou, E. Nikolsky et al., “Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic vari- ables,” American Journal of Cardiology, vol. 95, no. 1, pp. 13– 19, 2005. [27] C. J. Davidson, M. Hlatky, K. G. Morris et al., “Car- diovascular and renal toxicity of a nonionic radiographic